This edition of the Annals contains an article by Geberhiwot et al. describing how HbA 1c measurement may help avoid unnecessary oral glucose tolerance tests (OGTTs) in the diagnosis of type 2 diabetes. 1 The use of HbA 1c to diagnose diabetes is certainly appealing. It would obviate the need for the patient to attend testing while fasting and, if an OGTT was required, would address the problem associated with poor reproducibility of the 2 h glucose value. Thus, from both a patient and health-care provider perspective, it would be a much more convenient way of testing for the disease. There is also an argument that HbA 1c testing may be a more physiological assessment of glucose intolerance than the arti¢cial conditions of the OGTT.
However, one of the obvious di⁄culties in solely using HbA 1c as a substitute for the OGTT is that it compares a single test with a condition which can be diagnosed using two di¡erent criteria, namely the fasting plasma glucose (FPG) concentration and the 2 h value. We know that in some individuals --such as obese subjects --diabetes is more likely to be diagnosed on the FPG result, while in others --such as the elderly --it is more likely to be due to a diagnostic 2 h value. 2 So while the FPG cut-o¡ of 7.0 mmol/L was chosen because it roughly corresponded with a 2 h value of 11.1mmol/L, nearly a third of Europeans with diagnostic 2 h values have 'normal' (p6 mmol/L) FPGs, simply because they are a less obese population than the ones from which the new diagnostic criteria were established. 3 This in turn means that the utility of HbA 1c as a screening test for diabetes could vary depending on the demographics of age or weight in the particular population studied.
Not that this has prevented there being numerous previous studies designed to investigate the possibility, or otherwise, of using HbA 1c for this purpose. A metaanalysis of 34 studies con¢rmed that while an HbA 1c result above the upper reference limit can be relatively speci¢c for glucose intolerance, it is not especially sensitive. 4 In other words, a raised HbA 1c is likely to indicate developing or overt glucose intolerance, but a 'normal' value does not exclude it. This is consistent with studies into the biological variability of HbA 1c , which have found that non-diabetic subjects hover closely around a 'set point' within the 4--6% HbA 1c reference interval. 5 As a consequence, a subject with a usual HbA 1c of 4% would need to abnormally increase his/her glycation rate by 50% to match another nondiabetic subject with an HbA 1c of 6%. It is therefore not surprising that there can be overlap between the HbA 1c values of diabetes patients with those of nondiabetic subjects. Likewise, it is also not unexpected that a 'high-normal' (5.5--6%) HbA 1c can predict diabetes onset, since subjects with these results are likely to be a mixture of those who ordinarily have these concentrations together with others who are progressing to diabetes from lower initial values. 6 Undoubtedly aware of these di⁄culties, Geberhiwot et al. have not attempted to use HbA 1c as a screening test in its own right, but have rather sought to combine it with FPG to try to avoid unnecessary OGTTs. E¡ectively, therefore, they are using glycated haemoglobin as a surrogate for the 2 h glucose concentration. There is certainly evidence that HbA 1c correlates at least as well with post-prandial glucose excursions as it does with pre-meal glucose, 7 and, together with the speci¢city of high HbA 1c values for diabetes, the test has been used by them to triage the requirement for the laborious OGTT.
At least some of the reasons that we are still debating the use of HbA 1c in diagnosis (nearly three decades after its proven use in patients with established diabetes) relate to the analytical and inherent limitations of the test. Leaving aside the current HbA 1c standardization/harmonization debate, there remain issues around individuals with abnormal haemoglobins and anaemias, especially when the latter is secondary to haemolysis or iron de¢ciency. In addition, from an analytical perspective, HbA 1c is still not the most precisely measurable analyte, so an assay showing a 3% coe⁄cient of variation (CV) at the critical 6.0% HbA 1c value can show a di¡erence in excess of 0.7% HbA 1c within the same individual.
Given all these hurdles, it is di⁄cult to see how HbA 1c will ever supplant (or even complement) the measurement of glucose while the latter test remains the single means by which the diagnosis is decided. To a clinician, near-certainty in making a diagnosis using HbA 1c is not certain enough when deciding whether a person will now have an illness which has lifelong health, lifestyle and ¢nancial consequences for them.
For this situation to change, HbA 1c (a marker of glycation) would need to prove itself to be at least as good a predictor of diabetes complications as hyperglycaemia.
The evidence for the macrovascular (large vessel) complication risk remains con£icting, 8, 9 but the evidence for microvascular (small vessel) disease recently showed a marked superiority for HbA 1c , at least in patients with established type 1 diabetes. 10 Thus, while the current glucose criteria appears to hamper the use of HbA 1c in diabetes diagnosis, it is still possible that further research into complication risk could lead to its use in identifying the disease.
